Sumant Kulkarni's Stock Ratings

Canaccord Genuity Analyst

Sumant Kulkarni is an analyst at Canaccord Genuity. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

-7.60%

Smart Score

46.6%

Overall Average Return Percentile

22nd

Number of Ratings

48
Buy NowGet Alert
05/07/2024STOKBuy Now
Stoke Therapeutics
$16.1623.76%$21 → $20MaintainsBuyGet Alert
05/06/2024GHRSBuy Now
GH Research
$12.89140.55%$30 → $31MaintainsBuyGet Alert
05/02/2024NBIXBuy Now
Neurocrine Biosciences
$141.6515.78%$154 → $164MaintainsBuyGet Alert
04/30/2024ANVSBuy Now
Annovis Bio
$8.55204.09%$36 → $26MaintainsBuyGet Alert
04/26/2024SAGEBuy Now
Sage Therapeutics
$11.2551.11%$21 → $17MaintainsHoldGet Alert
04/23/2024ITCIBuy Now
Intra-Cellular Therapies
$65.3263.81%$100 → $107MaintainsBuyGet Alert
04/08/2024CRVOBuy Now
CervoMed
$22.25192.13%$50 → $65MaintainsBuyGet Alert
03/26/2024STOKBuy Now
Stoke Therapeutics
$16.1629.95%$18 → $21MaintainsBuyGet Alert
03/14/2024BTAIBuy Now
BioXcel Therapeutics
$2.10233.33%$18 → $7MaintainsBuyGet Alert
03/12/2024ACADBuy Now
ACADIA Pharmaceuticals
$15.15117.82%$40 → $33MaintainsBuyGet Alert
03/06/2024CARABuy Now
Cara Therapeutics
$0.771200.56%$11 → $10MaintainsBuyGet Alert
02/23/2024ITCIBuy Now
Intra-Cellular Therapies
$65.3253.09%$101 → $100MaintainsBuyGet Alert
02/20/2024BIIBBuy Now
Biogen
$231.5831.7%$310 → $305MaintainsBuyGet Alert
02/15/2024CRVOBuy Now
CervoMed
$22.25124.72% → $50Initiates → BuyGet Alert
12/29/2023ANVSBuy Now
Annovis Bio
$8.55321.05% → $36Initiates → BuyGet Alert
12/07/2023NBIXBuy Now
Neurocrine Biosciences
$141.655.89% → $150ReiteratesBuy → BuyGet Alert
09/13/2023NBIXBuy Now
Neurocrine Biosciences
$141.651.66%$132 → $144MaintainsBuyGet Alert
09/01/2023ZVRABuy Now
Zevra Therapeutics
$4.92306.5% → $20ReiteratesBuy → BuyGet Alert
09/01/2023CYBNBuy Now
Cybin
$0.351324.5% → $5ReiteratesBuy → BuyGet Alert
08/22/2023CMPSBuy Now
Compass Pathways
$8.18510.9%$60 → $50MaintainsBuyGet Alert
08/16/2023ZYNEBuy Now
Zynerba Pharmaceuticals
——$10 → $1.11DowngradeBuy → HoldGet Alert
08/15/2023ZVRABuy Now
Zevra Therapeutics
$4.92306.5%$19 → $20MaintainsBuyGet Alert
08/15/2023BTAIBuy Now
BioXcel Therapeutics
$2.10852.38%$76 → $20MaintainsBuyGet Alert
08/11/2023CYBNBuy Now
Cybin
$0.351324.5%$6 → $5MaintainsBuyGet Alert
08/08/2023SAGEBuy Now
Sage Therapeutics
$11.2586.67%$64 → $21DowngradeBuy → HoldGet Alert
08/03/2023ACADBuy Now
ACADIA Pharmaceuticals
$15.15150.83%$39 → $38MaintainsBuyGet Alert
08/02/2023NBIXBuy Now
Neurocrine Biosciences
$141.65-6.81%$130 → $132MaintainsBuyGet Alert
07/03/2023CYBNBuy Now
Cybin
$0.351609.4%$7 → $6MaintainsBuyGet Alert
06/12/2023BIIBBuy Now
Biogen
$231.5851.14%$330 → $350MaintainsBuyGet Alert
05/10/2023VYGRBuy Now
Voyager Therapeutics
$8.4565.68%$10 → $14MaintainsBuyGet Alert

Recent Analyst Stock Rating News

In-Depth Examination Of 5 Analyst Recommendations For Cara Therapeutics
Analyst Ratings For Intra-Cellular Therapies
Analyst Expectations For Stoke Therapeutics's Future
ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
The Analyst Landscape: 27 Takes On Biogen
The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
Where Biogen Stands With Analysts
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free